Ken Griffin Novo Cure LTD Transaction History

Citadel Advisors LLC

$483 Billion
Q2 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Novo Cure LTD stock. As of the latest transaction made, Citadel Advisors LLC holds 132,800 shares of NVCR stock, worth $2.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

132,800

Previous 120,400 10.3%

Holding current value

$2.2 Million

Previous $1.88 Million 20.89%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$11.83 - $24.05 $1.52 Million - $3.09 Million	128,524 Added 33.1%	516,863 $8.85 Million
Q1 2024 May 15, 2024	SELL	$12.42 - $17.29 $3.6 Million - $5.01 Million	-289,853 Reduced 42.74%	388,339 $6.07 Million
Q4 2023 Feb 14, 2024	BUY	$11.13 - $15.78 $79,924 - $113,316	7,181 Added 1.07%	678,192 $10.1 Million
Q3 2023 Nov 14, 2023	BUY	$16.15 - $42.35 $1.93 Million - $5.05 Million	119,275 Added 21.62%	671,011 $10.8 Million
Q2 2023 Aug 14, 2023	BUY	$40.29 - $82.51 $21.3 Million - $43.6 Million	528,223 Added 2246.51%	551,736 $22.9 Million
Q1 2023 May 15, 2023	BUY	$56.44 - $118.81 $1.22 Million - $2.57 Million	21,608 Added 1134.28%	23,513 $1.41 Million
Q4 2022 Feb 14, 2023	SELL	$63.98 - $85.37 $3.96 Million - $5.28 Million	-61,831 Reduced 97.01%	1,905 $139,000
Q3 2022 Nov 14, 2022	SELL	$67.99 - $89.57 $23.9 Million - $31.5 Million	-351,888 Reduced 84.66%	63,736 $4.84 Million
Q2 2022 Aug 15, 2022	BUY	$56.6 - $89.9 $3.83 Million - $6.08 Million	67,647 Added 19.44%	415,624 $28.9 Million
Q1 2022 May 16, 2022	BUY	$60.15 - $84.52 $13.3 Million - $18.7 Million	220,708 Added 173.42%	347,977 $28.8 Million
Q4 2021 Feb 14, 2022	SELL	$75.08 - $121.99 $359,257 - $583,722	-4,785 Reduced 3.62%	127,269 $9.56 Million
Q3 2021 Nov 15, 2021	BUY	$116.17 - $194.55 $2.38 Million - $3.99 Million	20,505 Added 18.38%	132,054 $15.3 Million
Q2 2021 Aug 16, 2021	BUY	$130.4 - $225.58 $1.25 Million - $2.17 Million	9,605 Added 9.42%	111,549 $24.7 Million
Q1 2021 May 17, 2021	BUY	$124.11 - $190.17 $3.94 Million - $6.04 Million	31,777 Added 45.29%	101,944 $13.5 Million
Q4 2020 Feb 16, 2021	SELL	$112.16 - $174.14 $15.6 Million - $24.2 Million	-138,882 Reduced 66.44%	70,167 $12.1 Million
Q3 2020 Nov 16, 2020	BUY	$58.05 - $111.31 $5.51 Million - $10.6 Million	94,912 Added 83.16%	209,049 $23.3 Million
Q2 2020 Aug 14, 2020	BUY	$57.2 - $74.41 $527,670 - $686,432	9,225 Added 8.79%	114,137 $6.77 Million
Q1 2020 May 15, 2020	BUY	$57.05 - $95.75 $282,739 - $474,537	4,956 Added 4.96%	104,912 $7.07 Million
Q4 2019 Feb 14, 2020	BUY	$68.3 - $93.8 $5.32 Million - $7.31 Million	77,905 Added 353.29%	99,956 $8.42 Million
Q3 2019 Nov 14, 2019	SELL	$61.86 - $97.8 $736,257 - $1.16 Million	-11,902 Reduced 35.05%	22,051 $1.65 Million
Q2 2019 Aug 14, 2019	SELL	$42.22 - $63.23 $1.53 Million - $2.29 Million	-36,238 Reduced 51.63%	33,953 $2.15 Million
Q1 2019 May 15, 2019	SELL	$31.96 - $56.12 $6.08 Million - $10.7 Million	-190,225 Reduced 73.05%	70,191 $0
Q4 2018 Feb 14, 2019	BUY	$28.72 - $52.63 $5.72 Million - $10.5 Million	199,111 Added 324.79%	260,416 $8.72 Million
Q3 2018 Nov 13, 2018	SELL	$32.0 - $52.4 $19.6 Million - $32.1 Million	-612,031 Reduced 90.9%	61,305 $0
Q2 2018 Aug 10, 2018	SELL	$19.85 - $32.0 $10.3 Million - $16.6 Million	-518,951 Reduced 43.53%	673,336 $0
Q1 2018 May 11, 2018	BUY	$19.3 - $23.65 $14.4 Million - $17.7 Million	748,125 Added 168.44%	1,192,287 $26 Million
Q4 2017 Feb 09, 2018	BUY	$16.3 - $21.9 $4.44 Million - $5.97 Million	272,697 Added 159.04%	444,162 $8.97 Million
Q3 2017 Nov 09, 2017	BUY	$18.05 - $21.75 $3.09 Million - $3.73 Million	171,465	171,465 $3.4 Million

Others Institutions Holding NVCR

# of Institutions

266

Shares Held

78.7M

Call Options Held

751K

Put Options Held

293K

View Full List

About NovoCure Ltd

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $1.74B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

More about NVCR

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account